COVID-19 Vaccine Acceptance Among Parents of Children With Multisystem Inflammatory Syndrome in Children.
Fiche du document
1 avril 2024
- doi: 10.1097/INF.0000000000004206
- issn: 0891-3668
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1097/INF.0000000000004206
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/38241661
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1532-0987
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_0C812855490A5
info:eu-repo/semantics/openAccess , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
Sujets proches
Childhood Youngsters Pedology (Child study) Kids (Children)Citer ce document
C. Sanchez et al., « COVID-19 Vaccine Acceptance Among Parents of Children With Multisystem Inflammatory Syndrome in Children. », Serveur académique Lausannois, ID : 10.1097/INF.0000000000004206
Métriques
Partage / Export
Résumé
Data on COVID-19 vaccine acceptability among parents of children with multisystem inflammatory syndrome (MIS-C) are limited. In this cohort of children with MIS-C, enrolled in the Swissped RECOVERY trial (NCT04826588), comparing intravenous immunoglobulins or methylprednisolone, who, in accordance with Swiss guidelines, were recommended for SARS-CoV-2 vaccination, 65% (73/112) of parents reported being vaccinated against SARS-CoV-2 before the MIS-C, while 70% were vaccinated after the MIS-C episode of their child. None of the children were vaccinated before the occurrence of the MIS-C, and only 9% (5/56) received the COVID-19 vaccine after the MIS-C. The predominant barriers to COVID-19 vaccination were concerns over potential side effects and insufficient support from their doctors. This emphasizes the crucial role of health care providers in promoting COVID-19 vaccination among children.
